1.Daniel, DG, Potkin, SG, Reeves, KR, Swift, RH, Harrigan, ER. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Beri). 2001;155:128–134.
2.Lesem, MD, Zajecka, JM, Swift, RH, Reeves, KR, Harrigan, ER. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry. 2001;62:12–18.
3.Brook, S, Walden, J, Benattia, I, Siu, CO, Romano, SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Beri). 2005;178:514–523.
4.Richelson, E, Souder, T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29–39.
5.Shapiro, DA, Renock, S, Arrington, E, et al. Aripiprazole, a novel atypical anti-psychotic drug with a unique and robust pharmacology. Neuropsycbopharmacol. 2003;28:1400–1411.
6.Weiner, DM, Meitzer, HY, Veinbergs, I, et al. The role of Ml muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacol. 2004;177:207–216.
7.Schmidt, AW, Lebel, LA, Howard, HR Jr, Zorn, SH. Ziprasidone: a novel anti-psychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197–201.
8.DeLeon, A, Patel, NC, Crismon, ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649–666.
9.Stahl, SM, Shayegan, DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(suppl 19):6–12.
10.Kroeze, WK, Hufeisen, SJ, Popadak, BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsycbopharmacol. 2003;28:519–526.
11.Duman, RS. Depression: a case of neuronal life and death? Biol Psychiatry. 2004;56:140–145.
12.Thome, J, Foley, P, Riederer, P. Neurotrophic factors and the maldevelopmen-tal hypothesis of schizophrenic psychoses. Review article. J Neural Tramm. 1998;105:85–100.
13.Arango, C, Kirkpatrick, B, Koenig, J. At issue: stress, hippocampal neuronal turnover, and neuropsychiatrie disorders. Schizophr Bull. 2001;27:477–480.
14.Garver, DL, Holcomb, JA, Christensen, JD. Cerebral cortical gray expansion assoeiated with two second-generation antipsychotics. Biol Psychiatry. 2005;58:62–66.
15.Prakash, C, Kamel, A, Cui, D, Whalen, RD, Miceli, JJ, Tweedie, D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol. 2000;49(suppl 1):35S–42S.
16.Beedham, C, Miceli, JJ, Obach, RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol. 2003;23:229–232.
17.Miceli, JJ, Wilner, KD, Hansen, RA. Single and multiple dose pharmacokinetics of ziprasidone under non-fasting conditions in healthymale volunteers. Br J Clin Pharmacol. 2000;49(suppl 1):5S–13S.
18.Hamelin, BA, Allard, S, Laplante, L, et al. The effect of timing of a standard meal on rhe pharmacokinetics and pharmacodynamics of the novel atypical antipsy-chotic agent ziprasidone. Pharmacotherapy. 1998;18:9–15.
19.Miceli, JJ, Smith, M, Robarge, L, Morse, T, Laurent, A. The effects of ketoconazole on ziprasidone pharmacokinetics: a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol. 2000;49(suppl 1):S71–S76.
20.Miceli, JJ, Anziano, RJ, Robarge, L, Hansen, RA, Laurent, A. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol. 2000; 49:(suppl 1):S65–S70.
21.Apseloff, G, Mullet, D, Wilner, KD, et al. The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. Br J Clin Pharmacol. 2000;49(suppl 1):S61–S64.
22.Obach, RS, Huynh, P, Allen, MC, Beedham, C. Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol. 2004;44:7–19.
23. Geodon (package insert), New York, NY: Pfizer, Inc.; December 2003.
24.Murray, S, Mandel, FS, Loebel, A. Optimal initial dosing of ziprasidone: clinical trial data. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
25.Mamo, D, Kapur, S, Shammi, CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818–825.
26.Weiden, PJ, Iqbal, N, Mendelowitz, AJ, Tandon, R, Zimbroff, DL, Ross, R. Best clinical practice with ziprasidone: Update after one year of experience. J Psych Pract. 2002;8:81–97.
27.Joyce, AT, Harrison, DJ, Ollendorf, DA. Effect of ziprasidone initial dosing on discontinuation. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
28.Pozzi, L, Acconcia, S, Ceglia, I, et al. Stimulation of 5-hydroxytryptamine (5-HT(2Q) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex. J Neurochem. 2002;82:93–100.
29.Bonaccorso, S, Meitzer, HY, Li, Z, et al. SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsycbopharmacol. 2002;27:430–441.
30.Harrigan, EP, Miceli, JJ, Anziano, R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24:62–69.
31.Daniel, DG. Tolerability of ziprasidone: an expanding perspective. J Clin Psychiatry. 2003;64(suppl 19):40–49.
32.Deutschman, DA, Deutschman, DH. High-dose ziprasidone: Efficacy and toler-ability in clinical practice. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
33.Miceli, JJ, Murray, S, Sallee, FR, Tensfeldt, TG, Versavel, M. Phamacokinetic and pharmacodynamic QTc profile of oral ziprasidone in pediatric and adult subjects following single-dose administration. Poster presenred at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
34.Lindenmayer, JP, Czobor, P, Volavka, J, et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry. 2004;65:551–556.
35.Lindenmayer, JP, Bernstein-Hyman, R, Grochowski, S, Bark, N. Psychopathology ot schizophrenia: initial validation of a 5-factor model. Psycbopatbology. 1990;28;22–31.
36.Potkin, SG, Anand, R, Alphs, L, Fleming, K. Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk fur suicide. Schizophr Res. 2003;59:59–66.
37.Heydebrand, G, Weiser, M, Rabinowitz, J, Hoff, AL, DeLisi, LE, Csernansky, JG. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res. 2004;68:1–9.
38.Goff, DC, Posever, T, Herz, L, et al. An exploratory haloperidol-conrrolled dosefinding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1998;18:296–304.
39.Addington, D, Pantelis, C, Dineen, M. Ziprasidone vs risperidone in schizophrenia: 52 weeks' comparative data. Poster presented at: the 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.
40.Simpson, GM, Glick, ID, Weiden, PJ, Romano, SJ, Siu, CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability ot ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:1837–1847.
41.Geddes, J, Freemantle, N, Hatrison, P, Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J. 2000;321:1371–1376.
42.Bagnali, AM, Joncs, L, Ginnclly, L, et al. A systematic review of atypical antipsy-chotic drugs in schizophrenia. Health Tech Assess. 2003;7(13):1–193.
43.Lieberman, JA, Stroup, TS, McEvoy, JP. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223.
44.Harrison, DJ, Joyce, AT, Olldendorf, DA. Impact of atypical agents on outcomes of care in schizophrenia. Poster presented at: 158th Annual Meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, GA.
45.Siris, SG. Depression in schizophrenia: perspective in the era of “Atypical” antipsychotic agents. Am J Psychiatry. 2000;157:1379–1389.
46.Keck, PE Jr, Reeves, KR, Harrigan, EP, et al. Ziprasidone in the short-term treat-mem of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol. 2001;21:27–35.
47.Daniel, DG, Zimbroff, DL, Potkin, SG, Reeves, KR, Harrigan, EP, Lakshminarayanan, M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsycbopharmacol. 1999;20:491–505.
48.Keck, P Jr, Butfenstein, A, Ferguson, J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Beri). 1998;140:173–184.
49.Kane, JM. Oral ziprasidone in the treatment of schizophrenia: a review of shortterm trials. J Clin Psychiatry. 2003;64(suppl 19):19–25.
50.Elvevag, B, Goldberg, TE. Cognitive impairmenr in schizophrenia is the core of the disorder. Crtt Rev Neurobiol. 2000;14:1–21.
51.Gleen, MF, Nuechterlein, KH, Gold, JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the N1MH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56:301–307.
52.Davalos, DB, Compagnon, N, Heinlein, S, Ross, RG. Neuropsychological deficits in children associated with increased familial risk for schizophrenia. Schizophr Res. 2004;67:123–130.
53.Palmer, BW, Heaton, RK, Paulsen, JS, et al. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology. 1997;11:437–446.
54.Harvey, PD, Keefe, RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158:176–184.
55.Heinrichs, RW, Zakzanis, KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12:426–445.
56.Harvey, PD, Meitzer, H, Simpson, GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res. 2004;66:101–113.
57.Harvey, PD, Siu, CO, Romano, S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapili: in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacol 2004;172:324–332.
58.Harvey, PD, Bowie, CR, Loebel, A. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a 6-month, randomized, double-blind comparison of ziprasidone vs. olanzapine. J Neuropsych Clin Neurosci. In press.
59.Hegarty, JD, Baldessarini, RJ, Tohen, M. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151:1409–1416.
60.Dickerson, FB, Ringel, N, Parents, F. Predictors of residential independence among outpatients with schizophrenia. Psychiatr Serv. 1999;5:515–519.
61.Macdonald, EM, Hayes, RL, Baglioni, AJ Jr. The quantity and quality of the social networks of young people with early psychosis compared with closely matched controls. Schizophr Res. 2000;46:25–30.
62.Haukka, J, Suvisaari, J, Lonnqvist, J. Fertility of patients with schizophrenia, their siblings, and the general population: a cohort study from 1950 to 1959 in Finland. Am J Psychiatry. 2003;160:460–463.
63.Purnine, DM, Carey, KB, Maistro, SM, Karey, MP. Assessing positive and negative symptoms in patients with schizophrenia and mood disorders. J Nerv Ment Dis. 2000;188:653–661.
64.Loebel, A, Siu, C, Romano, S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr. 2004;9:357–364.
66.Arato, M, O'Connor, R, Meitzer, HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17:207–215.
67.Schooler, NR. Maintaining symptom control: review of ziprasidone longterm efficacy data. J Clin Psychiatry. 2003;64(suppl 19):26–32.
68.Simpson, GM, Weiden, PJ, Loebel, A, Warrington, L, Yang, R. Ziprasidone: long-term post-switch efficacy in schizophrenia. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
69.O'Connor, R, Schooler, NR. Penulrimate observation carried forward (POCF): a new approach to analysis of long-term symptom change in chronic relapsing conditions [letter]. Schizophr Res. 2003;60:319–320.
70.Weiden, PJ, Simpson, GM, Potkin, SG, O'Sullivan, RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64:580–588.
71.Weiden, PJ, Daniel, DG, Simpson, GM, Romano, SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23:1–6.
72.Contey, RR, Buchanan, RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 1997;23:663–674.
73.Basu, A. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. Schizophr Res. 2004;71:445–462.
74.Essock, SM, Hargreaves, WA, Covell, NH. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharm Bull. 1996;32:683–697.
75.Rosenheck, R, Cramer, J, Xu, W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med. 1997;337:809–815.
76.Tuunainen, A, Wahlbeck, K, Gilbody, S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res. 2002;56:1–10.
77.Moncrieff, J. Clozapine, v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. Br J Psychiatry. 2003;183:161–166.
78.Kane, J, Khanna, S, Giller, E, Rajadhyaksha, S, Loebel, A, Siu, E. Efficacy and tolerability of ziprasidone in treatment-resistant schizophrenia. Int Clin Psychopharmacol. In press.
79.Rothschild, AJ. Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am. 1996;19:237–252.
80.Kessler, RC, McGonagle, KA, Zhao, S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comotbidity Survey. Arch Gen Psychiatry. 1994;51:8–19.
81.Rush, AJ, Thase, ME, Dube, S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry. 2003;53:743–753.
82.Kohler, CG, Lallart, EA. Postpsychotic depression in schizophrenia patients. Curr Psychiatry Rep. 2002;4:273–278.
83.Tohen, M, Goldberg, JF, Gonzalez-Pinto Arrillaga, AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60:1218–1226.
84.Tohen, M, Zhang, F, Keck, PE, et al. Olanzapine versus haloperidol in schizoaf-fective disorder, bipolar type. J Affect Disord. 2001;67:133–140.
85.Tohen, M, Jacobs, TG, Grundy, SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2000;57:841–849.
86.Tohen, M, Chengappa, KN, Suppes, T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59:62–69.
87.DelBello, MP, Schwiers, ML, Rosenberg, HL, Strakowski, SM. A double-blind, randomized, placebo-conrrolled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41:1216–1223.
88.Casey, DE, Daniel, DG, Wassef, AA, Tracy, KA, Wozniak, P, Sommerville, KW. Effect of divalproex combined with olanzapine ot risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 2003;28:182–192.
89.Brambilla, P, Barale, F, Soares, JC. Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacol. 2003;166:315–332.
90.Hirschfeld, RM, Keck, PE Jr, Kramer, M, et al. Rapid anrimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161:1057–1065.
91.Potkin, SG, Keck, P, Giller, E, Ice, K, Warrington, L, Mandel, FS. Ziprasidone in bipolar mania: efficacy across patient subgroups. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
92.Keck, PE, Potkin, S, Watrington, L, Loebel, A, Giller, E, Batzar, E. Efficacy and safety of ziprasidone in bipolar disorder: short- and long-term data. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
93.Papakostas, Gl, Petersen, TJ, Neirenberg, AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSR I-res istant major depressive disorder. J Clin Psychiatry. 2004;65:217–221.
94.Joukamaa, M, Heliovaara, M, Knekt, P, Aromaa, A, Raitasalo, R, Lehtinen, V. Mental disorders and cause-specific mortality. Br J Psychiatry. 2001;179:498–502.
95.Harris, EC, Barraclough, B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11–53.
96.Osby, U, Brandt, L, Correia, N, Ekbom, A, Sparen, P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844–850.
97.Jamison, KR. Suicide and bipolar disorder. J Clin Psychiatry. 2000;61(suppl 9):47–51.
98.Davidson, S, Judd, F, Jolley, D, Hocking, B, Thompson, S, Hyland, B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry. 2001;35:196–202.
99.Casey, DE, Haupt, DW, Newcomer, JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65(suppl 7):4–18.
100.Zhang, ZJ, Yao, KJ, Liu, W, et al. Effects of anripsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry. 2004;184:58–62.
101.Newcomer, J. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1): 1–93.
102.American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596–601.
103.Simpson, GM, Glick, ID, Weiden, PJ, Romano, SJ, Siu, CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:1837–1847.
104.Simpson, GM, Weiden, P, Pigott, T, Murray, S, Siu, CO, Romano, SJ. Six-month, blinded, multicenter conrinuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry. 2005;162:1535–1538.
105.Sorensen, SV, Leaderer, MC, Harrison, DJ, et al. Psychiatric and metabolic outcomes of antipsychotics in schizophrenia. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2005; New Yotk, NY.
106.Marder, SR, McQuade, RD, Stock, E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123–136.
107.Cheet, SM, Wagstaff, AJ. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs. 2004; 18(3): 173–199.
108.Fitzsimons, J, Berk, M, Lambert, T, Bourin, M, Dodd, S. A review of clozapine safety. Expert Opin Drug Saf. 2005;4(4):731–744.
109.Pajonk, FG. Risperidone in acute and long-term rherapy of schizophrenia--a clinical profile. Prog Neuropsycbopharmacol Biol Psychiatry. 2004;28(1):15–23.
110.Bhana, N, Foster, RH, Olney, R, Plosker, GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111–161.
111.Moller, HJ. Risperidone: a review. Expert Opin Pharmacother. 2005;6(5):803–818.
112.Swatnston Harrison, T, Perry, CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715–1736.
113. Clozaril (package insert). East Hanover, NJ: Novartis; January 2003.
114. Zyprexa (package insert). Indianapolis, IN: Eli Lilly; March 2004.
115. Abilify (package insert). Orsuka Pharmaceutical Co, Ltd (Tokyo) and Bristol-Myers Squibb (Princeton, NJ); March 2004.
116. Risperdal (package insert). Titusville, NJ: Janssen Pharmaceutical December 2003.
117. Seroquel (package insert). Wilmington, DE: AstraZeneca; January 2004.
118.Taylor, D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs. 2003;17:423–430.
119.Montanez, A, Ruskin, JN, Hebert, PR, Lamas, GA, Hennekens, CH. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population. Arch Int Med. 2004;164:943–948.
120.Goldberg, RJ, Bengtson, J, Chen, ZY, Anderson, KM, Locati, E, Levy, D. Duration of the QT interval and total and cardiovascular mortality in healthy persons (The Framingham Heart Study experience). Am J Cardiol. 1991;67:55–58.
121.Casey, DE, Haupt, DW, Newcomer, JW, et al. Antipsychotic-tnduced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65(suppl 7):4–18.
122.Allison, DB, Mentore, JL, Heo, M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686–1696.
123.Beasley, CM, Tollefson, GD, Tran, PV. Safety of olanzapine. J Clin Psychiatry. 1997;58:13–17.
124.Meyer, JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63:425–433.
125.Wilson, PW, D'Agostino, RB, Levy, D, Belanget, AM, Silbershatz, H, Kannel, WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847.
126.Wolf, PA, Abbott, RD, Kannet, WB. Atrial fibrillation as an independent risk factor for srroke: the Framingham Study. Stroke. 1991;22:983–988.
127.Harrison, DJ, Leaderer, MC, Loebel, A, Murray, S. Ziprasidone, vs. olanzapine: change in CHD risk during a 6 week trial. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; Atlanta, GA.
128.Newcomet, J, Lebovitz, H. Course of weight and metabolic benefits one-year after switching to ziprasidone. Posrer presented at: 157th Annual Meeting of the American Psychiarric Associarion; May 1-6, 2004; Atlanta, GA.
129.Street, JS, Clark, WS, Gannon, KS, et al. Olanzapine tteatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57:968–976.
130.De Deyn, PP, Carrasco, MM, Deberdt, W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patienrs wirh Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19:115–126.
131.Wooltorton, E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002;167:1269–1270.
133.Weiden, Pj, Mackell, J, Macdonell, D. Obesity as a risk factor for noncompliance. Schizophrenia Res. 2004;66:51–57.